Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: A retrospective evaluation from a UK centre

Pathogens and Global Health

Volumn 106, Issue 3, 2012, Pages 181-187

  Eder, Marcus ^a   Farne, Hugo ^a   Cargill, Tamsin ^a   Abbara, Aula ^a   Davidson, Robert N ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Adverse event; Artesunate; Clinical outcome; Effectiveness; Falciparum malaria; Hameolytic anaemia; Length of stay; Non endemic countries; Parasite clearance; Quinine; Returning traveler; Safety; Severe malaria; Side effects; UK

Indexed keywords

ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; DOXYCYCLINE; PREDNISOLONE; QUININE;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; HEMOLYTIC ANEMIA; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MORTALITY; PARASITE CLEARANCE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTEMISININS; DRUG TOXICITY; FEMALE; GREAT BRITAIN; HUMANS; LENGTH OF STAY; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; QUININE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRAVEL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866714640     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773212Y.0000000032     Document Type: Article

References (32)

1. Health Protection Agency. Health Prot. Rep. 2011;5:17-28. Available from: http://www.hpa.org.uk/hpr/archives/2011/hpr1711.pdf (accessed 28/03/2012).
2. Phillips A, Bassett P, Zeki S, Newman S, Pasvol G. Risk factors for severe disease in adults with falciparum malaria. Clin Infect Dis. 2009;48(7):871-8.
3. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94(Suppl 1):S1-90.
4. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, et al. UK malaria treatment guidelines. J Infect. 2007;54(2):111-21.
5. British Infection Society. Malaria - Algorithm for Initial Assessment and Management in Adults. Princes Risborough: BIS; 2007. Available from: http://www.britishinfection.org/drupal/sites/default/files/MalariaAlgorithm07.pdf (accessed 28/ 03/2012).
6. Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. Trans R Soc Trop Med Hyg. 1990;84(Suppl 2):1-65.
7. Day N, Dondorp AM. The management of patients with severe malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):29-35.
8. White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Krishna S, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med. 1983;309(2):61-6.
9. Bonington A, Davidson RN, Winstanley PA, Pasvol G. Fatal quinine cardiotoxicity in the treatment of falciparum malaria. Trans R Soc Trop Med Hyg. 1996;90(3):305-7.
10. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549-58.
11. Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv Pharmacol. 1997;37:253-97.
12. Wu Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc Chem Res. 2002;35(5):255-9.
13. Li W, Mo W, Shen D, Sun L, Wang J, Lu S, et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet. 2005;1(3):e36.
14. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol. 1993;76(1):85-95.
15. Hess KM, Goad JA, Arguin PM. Intravenous artesunate for the treatment of severe malaria. Ann Pharmacother. 2010;44(7-8):1250-8.
16. Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, et al. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol. 2006;62(12):1003-9.
17. Jones KL, Donegan S, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2007;(4):CD005967.
18. Krudsood S, Wilairatana P, Vannaphan S, Treeprasertsuk S, Silachamroon U, Phomrattanaprapin W, et al. Clinical experience with intravenous quinine, intramuscular artemether and intravenous artesunate for the treatment of severe malaria in Thailand. Southeast Asian J Trop Med Public Health. 2003;34(1):54-61.
19. Maude RJ, Plewes K, Faiz MA, Hanson J, Charunwatthana P, Lee SJ, et al. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? Am J Trop Med Hyg. 2009;80:126-32.
20. Newton PN, Angus BJ, Chierakul W, Dondorp A, Ruangveerayuth R, Silamut K, et al. Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis. 2003;37(1):7-16.
21. Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005; 366(9487):717-25.
22. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-57.
23. Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, et al. Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Health. 2009;14(3):332-7.
24. World Health Organization. Guidelines for the treatment of malaria 2nd edition. Geneva: WHO; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf (accessed 28/03/2012).
25. World Health Organization. Guidelines for the treatment of malaria 2nd edition - Rev. 1. Geneva: WHO; 2011. Available from: http://www.who.int/malaria/publications/atoz/mal_-treatchild_revised.pdf (accessed 28/03/2012).
26. Centers for Disease Control and Prevention. Artesunate is available to treat severe malaria in the United States, 8 February 2010. Available from: http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html (accessed 28/03/2012).
27. Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011;17(5):771-7.
28. Bartoloni A, Tomasoni L, Bartalesi F, Galli L, Sani S, Veloci S, et al. Combined intravenous treatment with artesunate and quinine for severe malaria in Italy. Am J Trop Med Hyg. 2010;83(2):274-6.
29. Mørch K, Strand Ø, Dunlop O, Berg A, Langeland N, Leiva RA, et al. Severe malaria and artesunate treatment, Norway. Emerg Infect Dis. 2008;14(11):1816-8.
30. Lesi AF, Meremikwu MM. High first dose quinine regimen for treating severe malaria. Cochrane Database Syst Rev. 2004;(3):CD003341.
31. Tariq M et al. Efficacy and safety of quinine loading dose in patients with severe falciparum malaria at a tertiary care hospital in Pakistan. J Pak Med Assoc. 2011;61(1):27-31.
32. Itoda I, Yasunami T, Kikuchi K, Yamaura H, Totsuka K, Yoshinaga K, et al. [Severe falciparum malaria with prolonged hemolytic anemia after successful treatment with intravenous artesunate]. Kansenshogaku Zasshi. 2002;76(8):600-3.Japanese.